An experimental pharmacokinetic computer program to predict potential drug-drug interactions

Open Drug Metabolism Journal

Volumn 3, Issue , 2009, Pages 8-16

  Zvada, Simbarashe Peter ^a,b   Chagwedera, Tangai Edwin ^b   Chigwanda, Rosemary ^b   Masimirembwa, Collen Mutowembwa ^a  

^a African Institute of Biomedical Science and Technology   (Zimbabwe)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INDUCING AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; COMPUTER PROGRAM; DATA BASE; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; INFORMATION RETRIEVAL; MALARIA; MICROCOMPUTER; PHARMACIST; PHARMACOKINETICS; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; TROPICAL DISEASE; TUBERCULOSIS;

EID: 70350566383     PISSN: None     EISSN: 18740731     Source Type: Journal    
DOI: 10.2174/1874073100903010008     Document Type: Article

References (32)

1. Gurwitz, J.H.; Field, T.S.; Judge, J.; Rochon, P.; Harrold, L.R.; Cadoret, C.; Lee, M.; White, K.; LaPrino, J.; Erramuspe-Mainard, J.; DeFlorio, M.; Gavendo, L.; Auger, J.; Bates, D.W. The incidence of adverse drug events in two large academic long-term care facilities. Am. J. Med., 2005, 118(3), 251-258.
2. Marschner, J.P.; Thurmann, P.; Harder, S.; Rietbrock, N. Drug utilization review on a surgical intensive care unit. Int. J. Clin. Pharmacol. Ther., 1994, 32(9), 447-451. (Pubitemid 24277053)
3. CQHCA: Institute of Medicine, Washington, D.C.: To err is human: building a safer health system. National Academy Press, 2000.
4. Gurwitz, J.H.; Field, T.S.; Avorn, J.; McCormick, D.; Jain, S.; Eckler, M.; Benser, M.; Edmondson, A.C.; Bates, D.W. Incidence and preventability of adverse drug events in nursing homes. Am. J. Med., 2000, 109(2), 87-94. (Pubitemid 30674505)
5. Vincent, C. Principles of risk and safety. Acta Neurochir. Suppl., 2001, 78, 3-11.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health organisation (WHO): EpiReport 2006. http://data.unaids.org/pub/EpiReport/2006/ 2006-EpiUpdate-en.pdf. (accessed July 11, 2007).
7. Jacubeit, T.; Drisch, D.; Weber, E. Risk factors as reflected by an intensive drug monitoring system. Agents Actions Suppl., 1990, 29, 117-125.
8. Leape, L.L.; Bates, D.W.; Cullen, D.J.; Cooper, J.; Demonaco, H. J.; Gallivan, T.; Hallisey, R.; Ives, J.; Laird, N.; Laffel, G.; et al. Systems analysis of adverse drug events. ADE Prevention Study Group. J. Am. Med. Assoc., 1995, 274(1), 35-43.
9. Huang, S.M.; Lesko, L.J. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J. Clin. Pharmacol., 2004, 44(6), 559-569.
10. Lin, J.H.; Lu, A.Y. Inhibition and Induction of Cytochrome P450 and the clinical Implications. Clin. Pharmacokinet., 1998, 35(5), 361-390. (Pubitemid 28520008)
11. Bapiro, T.E.; Egnell, A.C.; Hasler, J.A.; Masimirembwa, C.M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab. Dispos., 2001, 29(1), 30-35.
12. Bapiro, T.; Andersson, T.; Otter, C.; Hasler, J.; Masimirembwa, C. Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur. J. Clin. Pharmacol., 2002, 58(8), 537. (Pubitemid 35439154)
13. Li, X.-Q.; Bjorkman, A.; Andersson, T.B.; Ridderstrom, M.; Masimirembwa, C.M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther., 2002, 300(2), 399-407.
14. Cavuto, N.J.; Woosley, R.L.; Sale, M. Pharmacies and prevention of potentially fatal drug interactions. J. Am. Med. Assoc., 1996, 275(14), 1086-1087. (Pubitemid 26106968)
15. Smalley, W.; Shatin, D.; Wysowski, D.K.; Gurwitz, J.; Andrade, S.E.; Goodman, M.; Chan, K.A.; Platt, R.; Schech, S.D.; Ray, W.A. Contraindicated use of cisapride: impact of food and drug administration regulatory action. J. Am. Med. Assoc., 2000, 284(23), 3036-3039.
16. Bonnabry, P.; Sievering, J.; Leemann, T.; Dayer, P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions. Eur. J. Clin. Pharmacol., 1999, 55(5), 341-347. (Pubitemid 29344076)
17. Carlson, S.P.; Ragueneau-Majlessi, I.; Levy, R.H. In: Drug-Drug Interactions; Rodrigues, A.D. Ed.; New York: Marcel Dekker, Inc., 2001; Vol. 116, pp. 549-563.
18. Rodrigues, A.D.; Winchell, G.A.; Dobrinska, M.R. Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. Br. J. Clin. Pharmacol., 2001, 41(4), 368-373.
19. Brown, H.S.; Ito, K.; Galetin, A.; Houston, J.B. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol., 2005, 60(5), 508-518.
20. Galetin, A.; Burt, H.; Gibbons, L.; Houston, J.B. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos., 2006, 34(1), 166-175.
21. Wang, Y.H.; Jones, D.R.; Hall, S.D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos., 2004, 32(2), 259-266.
22. Mayhew, B.S.; Jones, D.R.; Hall, S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos., 2000, 28(9), 1031-1037.
23. Venkatakrishnan, K.; Obach, R.S. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab. Dispos., 2005, 33(6), 845-852.
24. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drugdrug interactions: metabolic interaction in the liver. Pharmacol. Rev., 1998, 50(3), 387-412. (Pubitemid 28477680)
25. Oberle, R.L.; Chen, T.S.; Lloyd, C.; Barnett, J.L.; Owyang, C.; Meyer, J.; Amidon, G.L. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology, 1990, 99(5), 1275-1282. (Pubitemid 20381860)
26. Kanamitsu, S.; Ito, K.; Sugiyama, Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res., 2000, 17(3), 336-343. (Pubitemid 30225138)
27. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K.; Gaman, E.A.; Houston, J.B.; Tremaine, L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 2006, 316(1), 336-348.
28. Rostami-Hodjegan, A.; Tucker, G.T. In silico simulations to assess the in vivo consequenses of in vitro metabolic drug-drug interactions. Drug Discov. Today Tech., 2004, 1, 221-448.
29. Grol, R.; Grimshaw, J. From best evidence to best practice: effective implementation of change in patients' care. Lancet, 2003, 362(9391), 1225-1230. (Pubitemid 37255352)
30. Kaushal, R.; Barker, K.N.; Bates, D.W. How can information technology improve patient safety and reduce medication errors in children's health care? Arch. Pediatr. Adolesc. Med., 2001, 155(9), 1002-1007.
31. Bates, D.W.; Cohen, M.; Leape, L.L.; Overhage, J.M.; Shabot, M.M.; Sheridan, T. Reducing the frequency of errors in medicine using information technology. J. Am. Med. Inform. Assoc., 2001, 8(4), 299-308. (Pubitemid 32641632)
32. Proctor, N.J.; Tucker, G.T.; Rostami-Hodjegan, A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica, 2004, 34(2), 151-178. (Pubitemid 38299716)